Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Press Release: Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 10:03 pm
reduced from -5.9% 'Off-Idebenone' to -1.9% 'On-Idebenone'. -- The annual rate of decline in FVC%p and PEF%p remained stable year after year for the entire follow-up time of up to six years and was ...
- Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 9:00 pm
Buyse, MD, PhD, Professor of Pediatrics and Child Neurology, University Hospitals Leuven (Leuven, Belgium). About Duchenne Muscular Dystrophy DMD is one of the most common and devastating types of ...
- A distant dream for us with muscular dystrophyon November 17, 2019 at 11:56 pm
Early symptoms include a wadding gait, pain and stiffness in muscles, difficulty sitting up or standing, walking on toes, frequent falls etc. Most common and severe form of muscular dystrophy is ...
- Becker muscular dystrophy caused by exon 2-truncating mutation of DMDon November 17, 2019 at 7:28 pm
Nonsense and frameshift mutations of the dystrophin (DMD) gene usually cause severe Duchenne muscular dystrophy (DMD). Interestingly, however, premature stop codons in exons 1 and 2 result in ...
- Duchenne Muscular Dystrophy Therapeutics Market Strategic Assessment by Top Players | Sarepta Therapeutics, Inc, Santhera Pharmaceuticalson November 13, 2019 at 8:33 pm
Nov 14, 2019 (WiredRelease via COMTEX) -- Duchenne Muscular Dystrophy Therapeutics Market by Growth 2020 – Technological Strategies, Business Advancements and Top-Vendor Landscape 2029, anticipated to ...
- Parent Project Muscular Dystrophy Launches New Duchenne Registry Appon November 12, 2019 at 4:23 pm
Leading Duchenne Organization Enhances 12-Year-Old Registry with New App, Empowering Families to Become Citizen Scientists by Contributing Data from the Palm of their Hand HACKENSACK, N.J., Nov. 12, ...
- University Of Pennsylvania Testing New Gene Therapy Targeting Duchenne Muscular Dystrophyon November 12, 2019 at 3:35 pm
PHILADELPHIA (CBS) — A new gene therapy treatment is being tested at the University of Pennsylvania to treat a rare kind of muscular dystrophy. It’s progressive and strikes mainly boys. One ...
- Trial of Gene Therapy for Duchenne Muscular Dystrophy Put on Holdon November 12, 2019 at 11:35 am
A clinical trial of a gene therapy for Duchenne muscular dystrophy has been halted after a patient suffered serious side effects following treatment, Reuters reports today (November 12). After ...
- Cresswell mum tells of her brave boys' battle with Duchenne Muscular Dystrophyon November 12, 2019 at 7:53 am
Elizabeth and Scott Ruthven were heartbroken when first their son Wyatt, four and then Garret aged two were told they had Duchenne Muscular Dystrophy, a progressive muscle wasting condition. There is ...
- Patek Philippe watch sells for $31M in charity auction for muscular dystrophyon November 11, 2019 at 11:48 am
Luc Pettavino, former chief executive officer of the Monaco Yacht Show, founded the Only Watch charity auction in 2005, after his son, Paul, was diagnosed with Duchenne muscular dystrophy, a ...
via Bing News